NIH: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21) [PD-16-036]

This FOA encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes.
Date deadline

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE).

 
Dates
Posted: November 17, 2015
Opened: January 16, 2016
Expires: January 8, 2019
 
For more information and to apply, go to http://grants.nih.gov/grants/guide/pa-files/PA-16-036.html